Precision BioSciences Inc


Prices are adjusted according to historical splits.

Precision BioSciences Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$92.17 million
Book Value:
Revenue TTM:
$30.56 million
Operating Margin TTM:
Gross Profit TTM:
$25.10 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Precision BioSciences Inc had its IPO on 2019-03-28 under the ticker symbol DTIL.

The company operates in the Healthcare sector and Biotechnology industry. Precision BioSciences Inc has a staff strength of 197 employees.

Stock update

Shares of Precision BioSciences Inc opened at $229.8 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of $218 - $232.1, and closed at $218.65.

This is a -4.91% slip from the previous day's closing price.

A total volume of 18,964 shares were traded at the close of the day’s session.

In the last one week, shares of Precision BioSciences Inc have increased by +1.49%.

Precision BioSciences Inc's Key Ratios

Precision BioSciences Inc has a market cap of $92.17 million, indicating a price to book ratio of 1.6174 and a price to sales ratio of 6.3895.

In the last 12-months Precision BioSciences Inc’s revenue was $30.56 million with a gross profit of $25.10 million and an EBITDA of $-89712000. The EBITDA ratio measures Precision BioSciences Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Precision BioSciences Inc’s operating margin was -319.02% while its return on assets stood at -31.58% with a return of equity of -197.62%.

In Q1, Precision BioSciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 164.7%.

Precision BioSciences Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-0.93 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Precision BioSciences Inc’s profitability.

Precision BioSciences Inc stock is trading at a EV to sales ratio of 0.0292 and a EV to EBITDA ratio of 0.5036. Its price to sales ratio in the trailing 12-months stood at 6.3895.

Precision BioSciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$204.50 million
Total Liabilities
$46.86 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Precision BioSciences Inc ended 2024 with $204.50 million in total assets and $0 in total liabilities. Its intangible assets were valued at $204.50 million while shareholder equity stood at $40.18 million.

Precision BioSciences Inc ended 2024 with $0 in deferred long-term liabilities, $46.86 million in other current liabilities, 1000.00 in common stock, $-453372000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $158.13 million and cash and short-term investments were $158.13 million. The company’s total short-term debt was $2,094,000 while long-term debt stood at $22.27 million.

Precision BioSciences Inc’s total current assets stands at $169.02 million while long-term investments were $8.16 million and short-term investments were $0. Its net receivables were $694000.00 compared to accounts payable of $701000.00 and inventory worth $0.

In 2024, Precision BioSciences Inc's operating cash flow was $-721000.00 while its capital expenditure stood at $721000.

Comparatively, Precision BioSciences Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Precision BioSciences Inc stock is currently trading at $218.65 per share. It touched a 52-week high of $2.21 and a 52-week low of $2.21. Analysts tracking the stock have a 12-month average target price of $6.29.

Its 50-day moving average was $209.05 and 200-day moving average was $209.48 The short ratio stood at 1.7 indicating a short percent outstanding of 0%.

Around 1508.3% of the company’s stock are held by insiders while 5062.6% are held by institutions.

Frequently Asked Questions About Precision BioSciences Inc

The stock symbol (also called stock or share ticker) of Precision BioSciences Inc is DTIL

The IPO of Precision BioSciences Inc took place on 2019-03-28

Similar Industry Stocks (Biotechnology)

Last Price
Trevena Inc (TRVN)

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.


302 East Pettigrew Street, Durham, NC, United States, 27701